Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver
Dupixent peak sales ambition raised to more than €13 billion
Chronic obstructive pulmonary disease 2023 pivotal readouts provide potential for additional Dupixent sales ambition upgrade
13 potential new medicines currently in the clinic to treat chronic inflammatory diseases, with 17 readouts expected by the end of 2024
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.